GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.46 No.1 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/795
|
タイトル: | RAYNAUD'S SYNDROME IMPROVED BY THE INTRAVENOUS ADMINISTRATION OF A THROMBOXANE SYNTHETASE INHIBITOR |
著者: | Tsuchihashi, Masayuki Tsunoda, Shigeru Kitaoka, Soichi Morita, Yasuhiro Yumura, Fumitoshi Yoshida, Kazumasa Hayashi, Masafumi Ariyoshi, George Dohi, Kazuhiro |
キーワード: | prostacyclin Raynaud's syndrome sodium ozagrel thromboxane synthetase inhibitor thromboxane A₂ |
発行日: | 1995年2月28日 |
出版者: | 奈良医学会 |
引用: | 奈良医学雑誌 Vol.46 No.1 p.25-30 |
抄録: | A 66-year-old man with multiple cerebral infarctions was treated with
sodium ozagral ; this was associated with an improvement in his Raynaud's syndrome
attributable to vibration-induced white finger disease. Sodium ozagrel selectively inhibits
thromboxane synthetase, reducing thromboxane A₂ (TXA₂) and also slightly increasing
prostacyclin (PGI₂) ; this leads to vasodilatation and the inhibition of platelet aggregation.
An imbalance between TXA₂ and PGI₂ caused by vascular endothelial injury is thought to
cause Raynaud's phenomenon. Sodium ozagrel appears to improve the symptoms of
Raynaud's syndrome by relatively increasing PGI₂, thus correcting the imbalance. Ozagrel,
which currently is being used to treat cerebral thrombosis and bronchial asthma, as well as
to improve vasospasm following subarachnoid hemorrhage, also may provide effective
relief in patients with Raynaud's syndrome. |
URI: | http://hdl.handle.net/10564/795 |
ISSN: | 04695550 13450069 |
出現コレクション: | Vol.46 No.1
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|